XLY News 66.81 06/11/2014 05:43:10 Consumer Discret Select Sector

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Consumer Discret Select Sector SPDR (XLY) 66.81 $XLY

How a Rising Economy Could Boost These 2 ETFs
Michael Bodman, The Motley Fool - Motley Fool - Tue May 13, 3:20PM CDT
Since the Great Recession ended in June 2009, the U.S. economy has expanded for almost five years, and the job market has improved. As the economy expands, cyclical stocks stand to gain.  Cyclicality refers to the sensitivity of a stock's price...

Powerhouse ETFs: Energy, Consumer Staples and Utilities Outperform
at The Street - Mon May 12, 12:03PM CDT
There are 11 Exchange Traded Funds that provide a conservative way to invest in specific sectors without the risk of stock picking.

That Was Fast -- Stocks Lose the 'Yellen Effect'
at The Street - Thu May 08, 4:27PM CDT
As expected, the glow from the Federal Reserve chief didn't last and most stocks fell.

Will Disney Earnings Spell Magic for Consumer ETFs? - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu May 08, 7:00AM CDT
Thanks to hit movie Frozen, Disney stock easily beat estimates and is looking like an interesting pick.

The 'Yellen Effect' Revitalizes Wall Street, for Now
at The Street - Wed May 07, 4:29PM CDT
The head of the Federal Reserve made sure she said all the right things.

XLY, MCD, FOXA, NKE: Large Outflows Detected at ETF
ETFChannel.com - Mon May 05, 9:51AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Consumer Discretionary Select Sector SPDR Fund where we have detected an approximate $57.8 million dollar outflow --...

Why the Stock Market Is So Confusing Right Now
at The Street - Mon May 05, 9:39AM CDT
Here's why the broader market has failed to break down, even as many of its components have been stumbling.

How to Trade a Market That Takes No Prisoners
at The Street - Mon Apr 28, 9:26AM CDT
This market is anything but easy for traders to navigate, but here are some key levels for you to watch this week.

Consumer Discretionary ETFs Gain Despite MCD Earnings - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 9:00AM CDT
Consumer Discretionary ETFs have been doing well despite the weakness in MCD earnings.

Chart of the Day: Returns by Sector - Real Time Insight
Todd Bunton - Zacks Investment Research - Tue Apr 08, 11:40AM CDT
Sector returns show a "flight to safety" so far this year. But will that trend continue? Let us know what you think!

This Is Not Your 2013 Snapback Market Anymore
at The Street - Mon Apr 07, 9:13AM CDT
Here's an attempt to figure out the meaning of the destruction taking place in the market.

3 Consumer Discretionary ETFs Set to Surge - ETF News And Commentary
Sweta Killa - ZACKS - Fri Apr 04, 1:00PM CDT
These consumer ETFs are poised to move higher on strengthening fundamentals and rising sentiments.

Utilities, Health Care Leading ETF Sectors
at The Street - Wed Apr 02, 9:15AM CDT
Here are some investments to get exposure to broad sectors in the economy.

Cracks Beneath the Market's Surface
at The Street - Tue Mar 25, 10:45AM CDT
Even though the market has hit new highs, weakness lurks below. What should you do as an investor?

An ETF Strategy for a Volatile Second Quarter
at The Street - Mon Mar 24, 10:28AM CDT
Selecting the right exchange-traded funds will help the investor play defense in this environment.

Time to Bet on Consumer Discretionary ETFs? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 9:00AM CDT
Is now the time to buy these consumer ETFs?
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Scent Dispensing Solution for Hunting Enthusiasts

Updated Category News Views 168

Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...

Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results

Updated Category News Views 295

Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...

Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices

Updated Category News Views 113

Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...

Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today

Updated Category News Views 116

Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...

Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates

Updated Category News Views 671

Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...

Continue Reading